drugset / Trial / NCT03989271

Summary

This study determines whether quercetin supplementation reduces the inflammation and oxidative stress markers in patients with chronic obstructive pulmonary disease. It is small study with 8 subjects receive quercetin 2000 mg/day and 4 subjects receive placebo.

Timeline

Start
2019-10-01
Primary completion
2024-05-30
Completion
2025-07-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Quercetin Small molecule 2000 mg Oral